This article, from RGA’s ReFlections, discusses how the FDA’s approval of TREGZI highlights the rapid evolution of cell-based therapies beyond cancer treatment and how engineered immune-cell approaches are being used to address serious complications associated with stem cell transplantation.
The Food and Drug Administration (FDA) has approved TREGZI™ in June 2026, clinically known as Orca-T®, the first regulatory T-cell (Treg) immunotherapy designed to improve chronic graft-versus-host disease (GVHD)-free survival in adults with high-risk blood cancers undergoing allogeneic stem cell transplantation. This approval represents a significant advance in cellular therapy and transplant medicine.
TREGZI is intended for patients with hematologic malignancies – such as acute leukemia and high-risk myelodysplastic syndrome – who require donor stem cell transplantation. While transplantation can be curative, a dreaded complication is chronic GVHD, in which donor immune cells attack the recipient’s tissues, leading to potentially severe and long-lasting organ damage, disability, and even death.
The therapy consists of three donor-derived cellular components: hematopoietic stem and progenitor cells (HSPCs), Tregs, and conventional T-cells. Tregs play a key role in controlling immune responses and maintaining immune tolerance. By introducing these cells in a carefully engineered composition, TREGZI aims to substantially reduce the risk of chronic GVHD while the patient’s immune system rebuilds.
The FDA approval was supported by results from a randomized clinical trial involving 187 patients. At one year, 78% of patients treated with TREGZI were alive and free from moderate to severe chronic GVHD, compared with 38.4% of patients receiving the standard transplantation protocol.
For health insurers, TREGZI may increase upfront treatment costs due to its highly specialized cellular manufacturing process but could generate substantial downstream savings by reducing chronic GVHD, hospitalizations, long-term immunosuppressive therapy, and disability-related expenses. TREGZI is expected to cost $428,000 as a one-off treatment.
For life insurers, improved transplant outcomes could potentially translate into better long-term survival and lower post-transplant mortality among eligible blood cancer patients. Nevertheless, insurers will need to monitor real-world outcomes, durability of benefit, evolving treatment costs, and market adoption before adjusting assumptions.
RGA experts are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to learn more about RGA's capabilities, resources, and solutions.
